Article
EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.
BMC cancer - 19 Sept 2024
Wu Fan, Li Nani, Wu Xiufeng, Chen Mulan, Huang Weiwei, Chen Xinhua, Hong Yi, Wang Lili, Chen Kan, Lin Lin, You Minjin, Liu Jian
Abstract excerpt
BACKGROUND: The prognosis of breast cancer patients with visceral metastasis (VM) is significantly worse than that of patients without VM. We aimed to evaluate EZH2 (enhancer of zeste homolog 2) mutation as a biomarker associated with VM. METHODS: Data from forty-nine patients with metastatic breast cancer (MBC) pathologically confirmed at our hospital between March 2016 and September 2018 were collected....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.